These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10361136)

  • 21. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
    Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
    Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A stable single-chain variable fragment expressing transfectoma demonstrates induction of idiotype-specific cytotoxic T-cells during early growth stages of a murine B-lymphoma.
    Laxmanan S; Stuart GW; Ghosh SK
    Cancer Immunol Immunother; 2001 Oct; 50(8):437-44. PubMed ID: 11726138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes.
    Wu JY; Gardner BH; Kushner NN; Pozzi LA; Kensil CR; Cloutier PA; Coughlin RT; Newman MJ
    Cell Immunol; 1994 Apr; 154(1):393-406. PubMed ID: 7907530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.
    Baxevanis CN; Gritzapis AD; Spanakos G; Tsitsilonis OE; Papamichail M
    Cancer Immunol Immunother; 1995 Jun; 40(6):410-8. PubMed ID: 7543022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
    McMenamin C; Holt PG
    J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.
    Kovacsovics-Bankowski M; Clark K; Benacerraf B; Rock KL
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4942-6. PubMed ID: 8506338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules.
    Takeshita T; Kozlowski S; England RD; Brower R; Schneck J; Takahashi H; DeLisi C; Margulies DH; Berzofsky JA
    Int Immunol; 1993 Sep; 5(9):1129-38. PubMed ID: 8241055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breaking tolerance to a tumor-associated viral superantigen as a basis for graft-versus-leukemia reactivity.
    Schirrmacher V; Müerköster S; Bucur M; Umansky V; Rocha M
    Int J Cancer; 2000 Sep; 87(5):695-706. PubMed ID: 10925364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sialoadhesin-positive macrophages bind regulatory T cells, negatively controlling their expansion and autoimmune disease progression.
    Wu C; Rauch U; Korpos E; Song J; Loser K; Crocker PR; Sorokin LM
    J Immunol; 2009 May; 182(10):6508-16. PubMed ID: 19414805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
    Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
    Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting to porcine sialoadhesin receptor improves antigen presentation to T cells.
    Revilla C; Poderoso T; Martínez P; Alvarez B; López-Fuertes L; Alonso F; Ezquerra A; Domínguez J
    Vet Res; 2009; 40(3):14. PubMed ID: 19081005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling pathogen-associated molecular patterns: Mycobacterium tuberculosis 19-kDa lipoprotein, CpG DNA, and lipopolysaccharide.
    Tobian AA; Potter NS; Ramachandra L; Pai RK; Convery M; Boom WH; Harding CV
    J Immunol; 2003 Aug; 171(3):1413-22. PubMed ID: 12874233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I.
    Glas R; Ohlén C; Höglund P; Kärre K
    J Exp Med; 1994 Feb; 179(2):661-72. PubMed ID: 8294874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.
    Hilburger Ryan M; Abrams SI
    Cancer Immunol Immunother; 2001 Jan; 49(11):603-12. PubMed ID: 11225991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.